TSH Biopharm (ROCO:8432) Beginning Cash Position: NT$560 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
87 GF Score
Price NT$50.50
GF Value NT$71.29
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is TSH Biopharm Beginning Cash Position?

TSH Biopharm ROCO:8432 +0.80% 87 Beginning Cash Position is NT$560 Mil as of Jun. 2026. GuruFocus rates ROCO:8432 with a GF Score™ of 87/100 and a GF Value™ of NT$71.29 (Modestly Undervalued). The stock has 2 warning signs investors should review.

TSH Biopharm's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$560 Mil.

TSH Biopharm's quarterly Beginning Cash Position declined from Dec. 2025 (NT$589 Mil) to Mar. 2026 (NT$465 Mil) but then increased from Mar. 2026 (NT$465 Mil) to Jun. 2026 (NT$560 Mil).

TSH Biopharm's annual Beginning Cash Position increased from Dec. 2023 (NT$489 Mil) to Dec. 2024 (NT$577 Mil) and increased from Dec. 2024 (NT$577 Mil) to Dec. 2025 (NT$588 Mil).

TSH Biopharm Beginning Cash Position Related Terms

TSH Biopharm Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm Beginning Cash Position Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 396.70 510.53 488.90 576.59 588.34

TSH Biopharm Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 507.63 544.18 588.64 464.54 559.66
ROCO:8432
87GF Score
TSH Biopharm Corp Ltd ROCO:8432
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$560 Mil mean?
TSH Biopharm (ROCO:8432) has a Beginning Cash Position of NT$560 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on TSH Biopharm and its competitors.
Is TSH Biopharm's Beginning Cash Position too high?
TSH Biopharm's current Beginning Cash Position is NT$560 Mil. Overall, TSH Biopharm has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Beginning Cash Position compare to ZTS?
TSH Biopharm's Beginning Cash Position of NT$560 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on TSH Biopharm and its competitors. TSH Biopharm's current Beginning Cash Position is NT$560 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.29, compared to a current price of NT$50.50 — trading 29.2% below its estimated fair value. The current Beginning Cash Position is NT$560 Mil. TSH Biopharm's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Beginning Cash Position is NT$560 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.50 is trading 29.2% below its estimated GF Value™ of NT$71.29. GuruFocus considers TSH Biopharm to be Modestly Undervalued.

Key valuation signals for ROCO:8432:

  • Beginning Cash Position: NT$560 Mil
  • GF Value™: NT$71.29 vs. price of NT$50.50 (29.2% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
87GF Score

Get the complete analysis for ROCO:8432

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.50
Price
NT$71.29
GF Value